Search results for " insulin-like growth factor"

showing 9 items of 9 documents

The role of extracellular calcium in bone metastasis

2016

AbstractThis review summarizes the role of extracellular calcium, as found present in the bone tissue, in the process of bone metastasis.

0301 basic medicinelcsh:Diseases of the musculoskeletal systemIGF insulin-like growth factorPGE-2 prostaglandin E-2Bone tissueFibroblast growth factorM-CSF macrophage colony-stimulating factorPDGF platelet-derived growth factorBone remodelingSK3 small conductance calcium-activated potassium channel 30302 clinical medicineERK extracellular signal-regulated kinaseTGFβ transforming growth factor betaBMP's bone morphogenetic proteinsbiologyAKT AKT8 virus oncogene cellular homologBone metastasislcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenshumanitiescAMP cyclic adenosine monophosphatemedicine.anatomical_structureOncologyRANKL030220 oncology & carcinogenesisIon channelsCaSR calcium-sensing receptorPTHrP parathyroid hormone-related proteinPlatelet-derived growth factor receptorResearch PaperTRP transient receptor potentialmedicine.medical_specialtychemistry.chemical_elementCalciumRANKL receptor activator of NF-κB ligandlcsh:RC254-28203 medical and health sciencesPLC phospholipase CInternal medicinemedicineExtracellularCaSRET-1 endothelin-1PTEN phosphatase and tensin homolog deleted on chromosome 10business.industryBone metastasismedicine.diseaseFGF fibroblast growth factor030104 developmental biologyEndocrinologyPSA prostate specific antigenchemistryCOPD chronic obstructive pulmonary diseasebiology.proteinCancer researchJNK jun N-terminal kinasePKA protein kinase ARANK receptor activator of NF-κBCalciumlcsh:RC925-935businessMAPK mitogen-activated protein kinaseJournal of Bone Oncology
researchProduct

SHIP2: A “NEW” Insulin Pathway Target for Aging Research

2014

Strong evidence suggests that systemic inflammation and central adiposity contribute to and perpetuate metabolic syndrome. All of these alterations predispose individuals to type 2 diabetes mellitus (T2DM), cardiovascular disease, as well as Alzheimer's disease (AD), all characterized by chronic inflammatory status. On the other hand, extensive abnormalities in insulin and insulin-like growth factor I (IGF-I) and IGF-II signaling mechanisms in brains with AD have been demonstrated, suggesting that AD could be a third form of diabetes. The Src homology domain-containing inositol 5-phosphatase 2 (SHIP2) has an important role in the insulin pathway because its over-expression causes impairment…

AdultAgingmedicine.medical_specialtymedicine.medical_treatmentDiseaseBiologySystemic inflammationPolymorphism Single Nucleotidepolymorphismchemistry.chemical_compounddomain-containing inositol 5-phosphatase 2 (SHIP2) insulin-like growth factor I (IGF-I) type 2 diabetes mellitus (T2DM)INFLAMMATIONGene FrequencyAlzheimer DiseaseDiabetes mellitusInternal medicinemedicineHumansInsulinSettore MED/05 - Patologia ClinicaSNPInositolAgedSettore MED/04 - Patologia GeneraleALZHEIMER’S DISEASEResearchInsulinInositol Polyphosphate 5-PhosphatasesNEURODEGENERATIONType 2 Diabetes Mellitusmedicine.diseasePhosphoric Monoester HydrolasesEndocrinologyDiabetes Mellitus Type 2chemistryImmunologySettore MED/26 - NeurologiaGeriatrics and Gerontologymedicine.symptomMetabolic syndromeSignal TransductionRejuvenation Research
researchProduct

Teprotumumab for Thyroid-Associated Ophthalmopathy

2017

Thyroid-associated ophthalmopathy, a condition commonly associated with Graves' disease, remains inadequately treated. Current medical therapies, which primarily consist of glucocorticoids, have limited efficacy and present safety concerns. Inhibition of the insulin-like growth factor I receptor (IGF-IR) is a new therapeutic strategy to attenuate the underlying autoimmune pathogenesis of ophthalmopathy.We conducted a multicenter, double-masked, randomized, placebo-controlled trial to determine the efficacy and safety of teprotumumab, a human monoclonal antibody inhibitor of IGF-IR, in patients with active, moderate-to-severe ophthalmopathy. A total of 88 patients were randomly assigned to r…

AdultMalemedicine.medical_specialty030209 endocrinology & metabolismDiseaseAdult; Aged; Antibodies Monoclonal; Diabetes Complications; Double-Blind Method; Exophthalmos; Female; Graves Ophthalmopathy; Humans; Hyperglycemia; Immunologic Factors; Insulin-Like Growth Factor I; Intention to Treat Analysis; Logistic Models; Male; Middle Aged; Quality of LifeAntibodies Monoclonal HumanizedPlaceboAntibodiesReceptor IGF Type 1law.inventionDiabetes ComplicationsGraves' ophthalmopathy03 medical and health sciences0302 clinical medicineDouble-Blind MethodRandomized controlled triallawInternal medicineMonoclonalmedicineClinical endpointExophthalmosHumansImmunologic FactorsInsulin-Like Growth Factor IAgedIntention-to-treat analysisTeprotumumabbusiness.industryAntibodies MonoclonalGeneral MedicineMiddle Agedmedicine.diseaseIntention to Treat AnalysisGraves OphthalmopathyLogistic ModelsHyperglycemiaMonoclonalImmunologyQuality of Life030221 ophthalmology & optometryFemalebusinessmedicine.drugNew England Journal of Medicine
researchProduct

Effects of a Carob-Pod-Derived Sweetener on Glucose Metabolism

2018

Background: Patients with type 2 diabetes mellitus (T2DM) have a higher incidence of cardiovascular (CV) events. The ingestion of high-glycemic index (GI) diets, specially sweetened beverage consumption, has been associated with the development of T2DM and CV disease. Objective: We investigated the effects of the intake of a sweetened beverage, obtained from natural carbohydrates containing pinitol (PEB) compared to a sucrose-enriched beverage (SEB) in the context of impaired glucose tolerance (IGT) and diabetes. Methods: The study was divided in three different phases: (1) a discovery phase where the plasma proteomic profile was investigated by 2-DE (two-dimensional electrophoresis) follow…

Blood GlucoseMaleProteomicstype 2 diabetes mellitusmedicine.medical_treatmentType 2 diabetes030204 cardiovascular system & hematologyBody Mass IndexImpaired glucose tolerance0302 clinical medicineInsulinInsulin-Like Growth Factor INutrition and DieteticsbiologyChemistryComplement C4aFabaceaeMiddle AgedHealthy Volunteerslcsh:Nutrition. Foods and food supplyNutritive SweetenersAdultmedicine.medical_specialtyAdolescentsweetenerBlood sugarlcsh:TX341-641030209 endocrinology & metabolismCarbohydrate metabolismArticleDiabetes Mellitus ExperimentalBeveragesinsulin-like growth factor03 medical and health sciencesYoung AdultInsulin resistanceDouble-Blind MethodInternal medicineDiabetes mellitusGlucose IntolerancemedicineAnimalsHumansC4A complementAgedGlycated HemoglobinPlant ExtractsInsulinOverweightmedicine.diseaseRatsRats Zuckerimpaired glucose tolerance; type 2 diabetes mellitus; sweetener; insulin-like growth factor; C4A complementDisease Models AnimalEndocrinologyimpaired glucose toleranceDiabetes Mellitus Type 2biology.proteinGLUT2InositolFood ScienceNutrients; Volume 10; Issue 3; Pages: 271
researchProduct

Transgene detection by digital droplet PCR

2014

Somatic gene therapy is a promising tool for the treatment of severe diseases. Because of its abuse potential for performance enhancement in sports, the World Anti-Doping Agency (WADA) included the term 'gene doping' in the official list of banned substances and methods in 2004. Several nested PCR or qPCR-based strategies have been proposed that aim at detecting long-term presence of transgene in blood, but these strategies are hampered by technical limitations. We developed a digital droplet PCR (ddPCR) protocol for Insulin-Like Growth Factor 1 (IGF1) detection and demonstrated its applicability monitoring 6 mice injected into skeletal muscle with AAV9-IGF1 elements and 2 controls over a 3…

Genetics and Molecular Biology (all)Gene Identification and AnalysisGene TransferBiochemistryPolymerase Chain Reaction796 Athletic and outdoor sports and gamesMiceMedicine and Health SciencesTransgenesInsulin-Like Growth Factor IIntramuscularMedicine (all)QRDependovirusDependoviruMedicineGenetic VectorResearch ArticleBiotechnologyHumanScienceGenetic VectorsReproducibility of ResultIn Vitro TechniquesInjections IntramuscularInjectionsBiomaterialsMolecular GeneticsTransgeneAnimals; Dependovirus; Erythropoietin; Genetic Vectors; Humans; In Vitro Techniques; Injections Intramuscular; Insulin-Like Growth Factor I; Mice; Polymerase Chain Reaction; Reproducibility of Results; Transgenes; Agricultural and Biological Sciences (all); Biochemistry Genetics and Molecular Biology (all); Medicine (all)Genetic ElementsGeneticsAnimalsHumansSports and Exercise MedicineMolecular Biology TechniquesMolecular BiologyErythropoietinClinical GeneticsBiochemistry Genetics and Molecular Biology (all)796 SportAnimalIn Vitro TechniqueGene AmplificationBiology and Life SciencesReproducibility of ResultsHuman GeneticsDNAAgricultural and Biological Sciences (all)Mutation
researchProduct

Isolated childhood growth hormone deficiency: a 30-year experience on final height and a new prediction model

2022

Purpose We aimed to evaluate the near-final height (nFHt) in a large cohort of pediatricpatients with growth hormone deficiency (GHD) and to elaborate a new predictive method of nFHt. Methods We recruited GHD patients diagnosed between 1987 and 2014 and followed-up until nFHt. To predict the values of nFHt, each predictor was run in a univariable spline. Results We enrolled 1051 patients. Pre-treatment height was -2.43 SDS, lower than parental height (THt) (-1.09 SDS, p < 0.001). The dose of recombinant human GH (rhGH) was 0.21mg/kg/week at start of treatment. nFHt was -1.08 SDS (height gain 1.27 SDS), higher than pre-treatment height (p < 0.001) and comparable to THt. 1.6% of the pat…

Insulin-like growth factor 1Human Growth HormoneEndocrinology Diabetes and MetabolismPubertyFinal height; Growth; Growth hormone deficiency; Growth hormone retesting; Insulin-like growth factor 1; LMG method; PredictionDwarfismGrowthBody HeightCohort StudiesEndocrinologySettore MED/38 - Pediatria Generale E SpecialisticaGrowth hormone retestingPituitaryFinal heightGrowth HormoneFinal height; Growth; Growth hormone deficiency; Growth hormone retesting; Insulin-like growth factor 1; LMG method; Prediction; Body Height; Child; Cohort Studies; Growth Hormone; Humans; Puberty; Dwarfism Pituitary; Human Growth HormoneHumansGrowth hormone deficiencyLMG methodDwarfism PituitaryPredictionChildFinal height Growth Growth hormone deficiency Growth hormone retesting Insulin-like growth factor 1 LMG method Prediction
researchProduct

Janus kinase (JAK) 2 V617F mutation as the cause of primary thrombocythemia in acromegaly with severe visceromegaly and divergence between growth hor…

2012

OBJECTIVE: An increased prevalence of hematological abnormalities is reported in acromegaly, but to date no reports about the presence of the Janus Kinase (JAK) 2 mutation in acromegalic patients have been described. DESIGN: We report the complex clinical presentation of the unique case, never described, of acromegaly due to GH-secreting pituitary adenoma associated with JAK2 V617F mutation. RESULTS: The patient shows primary thrombocythemia and myelofibrosis, due to JAK2 V617F mutation, severe visceromegaly and a peculiar clinical course of the disease characterized by discrepant values of GH and IGF-1 during somatostatin analog (SA) treatment despite a significant reduction in pituitary a…

Malemedicine.medical_specialtyTime FactorsEndocrinology Diabetes and MetabolismGrowth hormone receptorAcromegaly HGH IGF-1GastroenterologySettore MED/13 - EndocrinologiaCohort StudiesEndocrinologyPituitary adenomahemic and lymphatic diseasesInternal medicineAcromegalymedicineAnimalsHumansPituitary NeoplasmsInsulin-Like Growth Factor IRadiometryMyelofibrosisAgedJanus kinase 2biologyHuman Growth HormonePlatelet Countbusiness.industryJanus Kinase 2medicine.diseaseAcromegaly Growth hormone Insulin-like growth factor-1 Janus kinase 2 Growth hormone receptorEndocrinologyAcromegalyMutationPegvisomantbiology.proteinJanus kinasebusinessVisceromegalyFollow-Up StudiesThrombocythemia Essentialmedicine.drug
researchProduct

TRPA1 channel is a cardiac target of mIGF-1/SIRT1 signaling.

2014

Cardiac overexpression of locally acting muscle-restricted (m)IGF-1 and the consequent downstream activation of NAD+-dependent protein deacetylase sirtuin 1 (SIRT1) trigger potent cardiac antioxidative and antihypertrophic effects. Transient receptor potential (TRP) cation channel A1 (TRPA1) belongs to the TRP ion channel family of molecular detectors of thermal and chemical stimuli that activate sensory neurons to produce pain. Recently, it has been shown that TRPA1 activity influences blood pressure, but the significance of TRPA1 in the cardiovascular system remains elusive. In the present work, using genomic screening in mouse hearts, we found that TRPA1 is a target of mIGF-1/SIRT1 sign…

Member 1PhysiologyTransgeneHeart; Insulin-like growth factor-1; Member 1; Sirtuin 1; Subfamily A; Transient receptor potential cation channelBlood PressurePharmacologymedicine.disease_causeTransient receptor potential channelMiceTransient Receptor Potential ChannelsSirtuin 1Physiology (medical)medicineAnimalsMyocytes CardiacInsulin-Like Growth Factor IPromoter Regions GeneticTRPA1 Cation ChannelbiologySirtuin 1AntagonistIGF-1 SIRT1 TRPA1 micefood and beveragesHeartTransient receptor potential cation channelInsulin-like growth factor-1Subfamily APurinesbiology.proteinProtein deacetylaseAcetanilidesNAD+ kinaseSignal transductionCardiology and Cardiovascular Medicinepsychological phenomena and processesOxidative stressSignal Transduction
researchProduct

NephroCheck: should we consider urine osmolality?

2019

medicine.medical_specialtyLetterCritical Care030232 urology & nephrologyMEDLINEUrine030204 cardiovascular system & hematologyCritical Care and Intensive Care MedicineAcute Kidney Injury; Biomarkers Humans Insulin-Like Growth Factor Binding Proteins Research Design Tissue Inhibitor of Metalloproteinase-2 Urine Osmolar ConcentrationOsmolar Concentration03 medical and health sciences0302 clinical medicinemedicineHumansTissue Inhibitor of Metalloproteinase-2Intensive Care Medicinebusiness.industryOsmolar Concentrationlcsh:Medical emergencies. Critical care. Intensive care. First aidlcsh:RC86-88.9Acute Kidney InjuryInsulin-Like Growth Factor Binding ProteinsResearch DesignEmergency medicineUrine osmolalitybusinessBiomarkersCritical Care
researchProduct